Research

Energy balance

82.7% of participants received no further prescriptions for antiobesity medications (AOMs) after their initial prescription.

This indicates a potential gap in ongoing obesity management for these patients.

StrongSupportsmedium confidence
82.7% receiving no further prescriptions for AOMs that year.
Dehshini Ali et al. · Diabetes Obesity and Cardiometabolic CARE · 2026

Why this rating

Based on a retrospective cohort study design.

Source

Patterns of Prescription Discontinuation, Reinitiation, and Switching of Subcutaneous Semaglutide and Tirzepatide in Adults With Obesity

Dehshini Ali et al. · Diabetes Obesity and Cardiometabolic CARE · 2026

DOI 10.2337/doc25-0026

cohort · n=9189
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →